Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials

被引：1256

作者：

Bhala, N. ^{[1
]}

Emberson, J. ^{[1
]}

Merhi, A. ^{[1
]}

Abramson, S. ^{[1
]}

Arber, N. ^{[1
]}

Baron, J. A. ^{[1
]}

Bombardier, C. ^{[1
]}

Cannon, C. ^{[1
]}

Farkouh, M. E. ^{[1
]}

FitzGerald, G. A. ^{[1
]}

Goss, P. ^{[1
]}

Halls, H. ^{[1
]}

Hawk, E. ^{[1
]}

Hawkey, C. ^{[1
]}

Hennekens, C. ^{[1
]}

Hochberg, M. ^{[1
]}

Holland, L. E. ^{[1
]}

Kearney, P. M. ^{[1
]}

Laine, L. ^{[1
]}

Lanas, A. ^{[1
]}

Lance, P. ^{[1
]}

Laupacis, A. ^{[1
]}

Oates, J. ^{[1
]}

Patrono, C. ^{[1
]}

Schnitzer, T. J. ^{[1
]}

Solomon, S. ^{[1
]}

Tugwell, P. ^{[1
]}

Wilson, K. ^{[1
]}

Wittes, J. ^{[1
]}

Baigent, C. ^{[1
]}

Adelowo, O. ^{[1
]}

Aisen, P. ^{[1
]}

Al-Quorain, A. ^{[1
]}

Altman, R. ^{[1
]}

Bakris, G. ^{[1
]}

Baumgartner, H. ^{[1
]}

Bresee, C. ^{[1
]}

Carducci, M. ^{[1
]}

Chang, D-M. ^{[1
]}

Chou, C-T. ^{[1
]}

Clegg, D. ^{[1
]}

Cudkowicz, M. ^{[1
]}

Doody, L. ^{[1
]}

El Miedany, Y. ^{[1
]}

Falandry, C. ^{[1
]}

Farley, J. ^{[1
]}

Ford, L. ^{[1
]}

GarciLosa, M. ^{[1
]}

Gonzalez-Ortiz, M. ^{[1
]}

Haghighi, M. ^{[1
]}

机构：

[1] Nuffield Dept Clin Med, Clin Trial Serv Unit, Oxford OX3 7LF, England

来源：

LANCET | 2013年 / 382卷 / 9894期

基金：

英国医学研究理事会;

关键词：

LOW-DOSE ASPIRIN; INHIBITORS PARECOXIB; CARDIOVASCULAR RISK; NAPROXEN; SAFETY; COMPLICATIONS; EFFICACY; PHARMACOLOGY; VALDECOXIB; ROFECOXIB;

D O I：

10.1016/S0140-6736(13)60900-9

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background The vascular and gastrointestinal effects of non-steroidal anti-inflammatory drugs (NSAIDs), including selective COX-2 inhibitors (coxibs) and traditional non-steroidal anti-inflammatory drugs (tNSAIDs), are not well characterised, particularly in patients at increased risk of vascular disease. We aimed to provide such information through meta-analyses of randomised trials. Methods We undertook meta-analyses of 280 trials of NSAIDs versus placebo (124 513 participants, 68 342 person-years) and 474 trials of one NSAID versus another NSAID (229 296 participants, 165 456 person-years). The main outcomes were major vascular events (non-fatal myocardial in farction, non-fatal stroke, or vascular death); major coronary events (non-fatal myocardial infarction or coronary death); stroke; mortality; heart failure; and upper gastrointestinal complications (perforation, obstruction, or bleed). Findings Major vascular events were increased by about a third by a coxib (rate ratio [RR] 1.37, 95% CI 1.14-1.66; p=0.0009) or diclofenac (1.41, 1.12-1.78; p=0.0036), chiefly due to an increase in major coronary events (coxibs 1.76, 1.31-2.37; p=0.0001; diclofenac 1.70, 1.19-2.41; p=0.0032). Ibuprofen also significantly increased major coronary events (2.22, 1.10-4.48; p=0.0253), but not major vascular events (1.44, 0.89-2.33). Compared with placebo, of 1000 patients allocated to a coxib or diclofenac for a year, three more had major vascular events, one of which was fatal. Naproxen did not significantly increase major vascular events (0.93, 0.69-1.27). Vascular death was increased significantly by coxibs (1.58, 99% CI 1.00-2.49; p=0.0103) and diclofenac (1.65, 0.95-2.85, p=0.0187), nonsignificantly by ibuprofen (1.90, 0.56-6.41; p=0.17), but not by naproxen (1.08, 0.48-2.47, p=0.80). The proportional effects on major vascular events were independent of baseline characteristics, including vascular risk. Heart failure risk was roughly doubled by all NSAIDs. All NSAID regimens increased upper gastrointestinal complications (coxibs 1.81, 1.17-2.81, p=0.0070; diclofenac 1.89, 1.16-3.09, p=0.0106; ibuprofen 3.97, 2.22-7.10, p<0.0001; and naproxen 4.22, 2.71-6.56, p<0.0001). Interpretation The vascular risks of high-dose diclofenac, and possibly ibuprofen, are comparable to coxibs, whereas high-dose naproxen is associated with less vascular risk than other NSAIDs. Although NSAIDs increase vascular and gastrointestinal risks, the size of these risks can be predicted, which could help guide clinical decision making.

引用

页码：769 / 779

页数：11

共 31 条

[1] COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS [J].

ALTMAN, R ;

CARRERAS, L ;

DIAZ, R ;

FIGUEROA, E ;

PAOLASSO, E ;

PARODI, JC ;

CADE, JF ;

DONNAN, G ;

EADIE, MJ ;

GAVAGHAN, TP ;

OSULLIVAN, EF ;

PARKIN, D ;

RENNY, JTG ;

SILAGY, C ;

VINAZZER, H ;

ZEKERT, F ;

ADRIAENSEN, H ;

BERTRANDHARDY, JM ;

BRAN, M ;

DAVID, JL ;

DRICOT, J ;

LAVENNEPARDONGE, E ;

LIMET, R ;

LOWENTHAL, A ;

MORIAU, M ;

SCHAPIRA, S ;

SMETS, P ;

SYMOENS, J ;

VERHAEGHE, R ;

VERSTRAETE, M ;

ATALLAH, A ;

BARNETT, H ;

BATISTA, R ;

BLAKELY, J ;

CAIRNS, JA ;

COTE, R ;

CROUCH, J ;

EVANS, G ;

FINDLAY, JM ;

GENT, M ;

LANGLOIS, Y ;

LECLERC, J ;

NORRIS, J ;

PINEO, GF ;

POWERS, PJ ;

ROBERTS, R ;

SCHWARTZ, L ;

SICURELLA, J ;

TAYLOR, W ;

THEROUX, P .

BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921) :81-100

[2]

[Anonymous], 2002, J RHEUMATOL, V29, P804

[3]

[Anonymous], HLTH TECHNOLOGY ASSE

[4]

[Anonymous], 1990, TREATM EARL BREAST C

[5] Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials [J].

Baigent, C. ;

Blackwell, L. ;

Emberson, J. ;

Holland, L. E. ;

Reith, C. ;

Bhala, N. ;

Peto, R. ;

Barnes, E. H. ;

Keech, A. ;

Simes, J. ;

Collins, R. .

LANCET, 2010, 376 (9753) :1670-1681

[6] ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents [J].

Bhatt, Deepak L. ;

Scheiman, James ;

Abraham, Neena S. ;

Antman, Elliott M. ;

Chan, Francis K. L. ;

Furberg, Curt D. ;

Johnson, David A. ;

Mahaffey, Kenneth W. ;

Quigley, Eamonn M. ;

Harrington, Robert A. ;

Bates, Eric R. ;

Bridges, Charles R. ;

Eisenberg, Mark J. ;

Ferrari, Victor A. ;

Hlatky, Mark A. ;

Kaul, Sanjay ;

Lindner, Jonathan R. ;

Moliterno, David J. ;

Mukherjee, Debabrata ;

Schofield, Richard S. ;

Rosenson, Robert S. ;

Stein, James H. ;

Weitz, Howard H. ;

Wesley, Deborah J. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 52 (18) :1502-1517

[7] Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. [J].

Bombardier, C ;

Laine, L ;

Reicin, A ;

Shapiro, D ;

Burgos-Vargas, R ;

Davis, B ;

Day, R ;

Ferraz, MB ;

Hawkey, CJ ;

Hochberg, MC ;

Kvien, TK ;

Schnitzer, TJ ;

Weaver, A .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (21) :1520-1528

[8] Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial [J].

Bresalier, RS ;

Sandler, RS ;

Quan, H ;

Bolognese, JA ;

Oxenius, B ;

Horgan, K ;

Lines, C ;

Riddell, R ;

Morton, D ;

Lanas, A ;

Konstam, MA ;

Baron, JA .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (11) :1092-1102

[9] Human pharmacology of naproxen sodium [J].

Capone, Marta L. ;

Tacconelli, Stefania ;

Sciulli, Maria G. ;

Anzellotti, Paola ;

Di Francesco, Luigia ;

Merciaro, Gabriele ;

Di Gregorio, Patrizia ;

Patrignani, Paola .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2007, 322 (02) :453-460

[10] Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects [J].

Capone, ML ;

Tacconelli, S ;

Sciulli, MG ;

Grana, M ;

Ricciotti, E ;

Minuz, P ;

Di Gregorio, P ;

Merciaro, G ;

Patrono, C ;

Patrignani, P .

CIRCULATION, 2004, 109 (12) :1468-1471

← 1 2 3 4 →